Earnings Summary

Blueprint Medicines Corp’s revenue jumped 51.87% since last year same period to $96.12Mn in the Q1 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 33.57% jump in its revenue since last 3-months.

Blueprint Medicines Corp’s net profit jumped 168.8% since last year same period to $89.14Mn in the Q1 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 180.36% jump in its net profits since last 3-months.

Blueprint Medicines Corp’s net profit margin jumped 145.3% since last year same period to 92.74% in the Q1 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated 160.16% jump in its net profit margins since last 3-months.

Blueprint Medicines Corp’s earning per share (EPS) estimates for the current year stand at -1.66.

Blueprint Medicines Corp’s earning per share (EPS) jumped 165.12% since last year same period to 1.4 in the Q1 2024. This indicates that the Blueprint Medicines Corp has generated 165.12% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Blueprint Medicines Corp’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Blueprint Medicines Corp’s return on equity (ROE) stands at -0.8.